Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GTX Regimen for Adjuvant Pancreatic Cancer
NCT00882310Phase 2Completed
- Sponsor
- Columbia University
- Start
- Sep 2006
- Primary completion
- Oct 2014
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine, docetaxel and capecitabine in pancreatic cancer (PC), sponsored by Columbia University. Primary endpoint: Dose Limiting Toxicities. Started Sep 2006; status: completed.
02
Drugs
gemcitabinedocetaxelcapecitabine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00882310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00882310.